Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Research & Development (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Research & Development for 4 consecutive years, with $330589.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 20.43% to $330589.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 6.88% decrease, with the full-year FY2024 number at $1.5 million, changed 0.46% from a year prior.
  • Research & Development was $330589.0 for Q3 2025 at bioAffinity Technologies, up from $311372.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $432818.0 in Q4 2023 to a low of $248419.0 in Q2 2022.
  • A 4-year average of $354475.6 and a median of $367386.0 in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 34.9% in 2023, then dropped 22.63% in 2025.
  • bioAffinity Technologies' Research & Development stood at $429236.0 in 2022, then increased by 0.83% to $432818.0 in 2023, then dropped by 9.74% to $390658.0 in 2024, then decreased by 15.38% to $330589.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Research & Development are $330589.0 (Q3 2025), $311372.0 (Q2 2025), and $367386.0 (Q1 2025).